Week 96 Efficacy and Safety of Darunavir/Ritonavir Monotherapy vs. Darunavir/Ritonavir with Two Nucleoside Reverse Transcriptase Inhibitors in the PROTEA Trial - Sorbonne Université
Journal Articles HIV medicine Year : 2017

Week 96 Efficacy and Safety of Darunavir/Ritonavir Monotherapy vs. Darunavir/Ritonavir with Two Nucleoside Reverse Transcriptase Inhibitors in the PROTEA Trial

Domains

Life Sciences [q-bio]

Gestionnaire HAL 4 Sorbonne Université  : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-03703933

Submitted on : Friday, June 24, 2022-2:13:07 PM

Last modification on : Thursday, December 14, 2023-1:50:38 PM

Consult the full text

Dates and versions

hal-03703933 , version 1 (24-06-2022)

Identifiers

Cite

Pm Girard, A Antinori, J. R. Arribas, D Ripamonti, C Bicer, et al.. Week 96 Efficacy and Safety of Darunavir/Ritonavir Monotherapy vs. Darunavir/Ritonavir with Two Nucleoside Reverse Transcriptase Inhibitors in the PROTEA Trial. HIV medicine, 2017, 18 (1), pp.5--12. ⟨10.1111/hiv.12386⟩. ⟨hal-03703933⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INSERM UPMC IPLESP SORBONNE-UNIVERSITE SU-MEDECINE
9 View
0 Download

Altmetric

Share

More